Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NHS Stock Summary
Top 10 Correlated ETFs
NHS
In the News

83 Monthly-Paying Dividend Stocks And 80 Funds For May
Imagine stocks or funds that pay out their dividends once-a-month! Unlike waiting for quarterly, semi-annual or (ugh) annual payouts, your angst waiting for money is reduced by 300%, or more! These May U.S. exchange-traded monthly-paid (MoPay) dividends, upsides, and net gains include: 1. Stocks by yield (83); 2. Stocks by price upside (30); 3. Closed-End Investments, Exchange-Traded Funds & Notes (CEICs/ETFs/ETNs) by yield >9.56% (80).

NHS: 2023 Rights Offering Quick Notes
Quick notes on Neuberger Berman High Yield Strategies' rights offering this year. Our suggestion is to sell before the ex-rights date and rebuy after the offering.

NHS: Time To Reduce Some Exposure To This High Beta HY CEF
NHS is a fixed income closed end fund. The fund focuses on U.S. high yield bonds, which represent 88% of the portfolio.

NHS: 13% Yield From A High Duration Bond CEF
NHS is a fixed income closed end fund. Over 88% of the fund holdings are fixed rate high yield bonds.

The Month In Closed-End Funds: October 2022
For the first month in three, equity CEFs (+4.49%) on average witnessed plus-side returns, while their fixed income CEF cohorts (-5.07%) suffered a third month of declines in October. Only 17% of all CEFs traded at a premium to their NAV at month end, with 24% of equity CEFs and 11% of fixed income CEFs trading in premium territory.

NHS: Rights Offering Quick Notes
NHS's rights offering is now live. The subscription formula has a floor of a -13% discount, at which point one should not subscribe.

Neuberger Berman High Yield Strategies Fund Announces Monthly Distribution
NEW YORK, Sept. 30, 2021 /PRNewswire/ -- Neuberger Berman High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced a distribution declaration of $0.0905 per share of common stock.

Neuberger Berman High Yield Strategies Fund Announces Monthly Distribution
NEW YORK , Aug. 31, 2021 /PRNewswire/ -- Neuberger Berman High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced a distribution declaration of $0.0905 per share of common stock. The distribution announced today is payable on September 30, 2021, has a record date of September 15, 2021 and has an ex-date of September 14, 2021.

Evaluating CEFs: NHS Too Expensive For Its Weak Distribution Coverage
The 8.6% yield for NHS looks very attractive if the distribution can be supported. I continue my series looking beyond the yield of a CEF.

Neuberger Berman High Yield Strategies Fund Announces Monthly Distribution
NEW YORK, July 30, 2021 /PRNewswire/ -- Neuberger Berman High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced a distribution declaration of $0.0905 per share of common stock. The distribution announced today is payable on August 31, 2021, has a record date of August 16, 2021 and has an ex-date of August 13, 2021.
NHS Financial details
NHS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-10-31
Metric | History | 2018-10-31 | 2019-10-31 | 2020-10-31 | 2021-10-31 | 2022-10-31 |
---|---|---|---|---|---|---|
Revenue per share | -0.04 | 1.31 | 0.32 | 1.68 | -1.73 | |
Net income per share | -0.16 | 1.16 | 0.16 | 1.53 | -1.91 | |
Operating cash flow per share | 0.83 | 1.08 | 1.12 | 5.95 | -2.78 | |
Free cash flow per share | 0.83 | 1.08 | 1.12 | 5.95 | -2.78 | |
Cash per share | 0 | 0.04 | 0 | 0 | 0 | |
Book value per share | 12.59 | 12.75 | 12.14 | 10.34 | 9.61 | |
Tangible book value per share | 12.59 | 12.75 | 12.14 | 10.34 | 9.61 | |
Share holders equity per share | 12.59 | 12.75 | 12.14 | 10.34 | 9.61 | |
Interest debt per share | 4.8 | 4.81 | 1.84 | 1.68 | 2.68 | |
Market cap | 199.67M | 231.66M | 203.04M | 230.15M | 143.8M | |
Enterprise value | 289.55M | 320.82M | 235.63M | 259.19M | 189.69M | |
P/E ratio | -64.56 | 10.28 | 67.19 | 8.59 | -4.29 | |
Price to sales ratio | -239.2 | 9.08 | 33.47 | 7.8 | -4.73 | |
POCF ratio | 12.47 | 11.06 | 9.59 | 2.21 | -2.95 | |
PFCF ratio | 12.47 | 11.06 | 9.59 | 2.21 | -2.95 | |
P/B Ratio | 0.82 | 0.94 | 0.89 | 1.27 | 0.85 | |
PTB ratio | 0.82 | 0.94 | 0.89 | 1.27 | 0.85 | |
EV to sales | -346.87 | 12.58 | 38.84 | 8.78 | -6.24 | |
Enterprise value over EBITDA | -2.1K | 12.37 | 45.95 | 9.52 | -5.84 | |
EV to operating cash flow | 18.09 | 15.31 | 11.13 | 2.49 | -3.9 | |
EV to free cash flow | 18.09 | 15.31 | 11.13 | 2.49 | -3.9 | |
Earnings yield | -0.02 | 0.1 | 0.01 | 0.12 | -0.23 | |
Free cash flow yield | 0.08 | 0.09 | 0.1 | 0.45 | -0.34 | |
Debt to equity | 0.55 | 0.55 | 0.57 | 0.62 | 0.75 | |
Debt to assets | 0.36 | 0.35 | 0.36 | 0.38 | 0.43 | |
Net debt to EBITDA | -652.84 | 3.44 | 6.36 | 1.07 | -1.41 | |
Current ratio | 0 | 1.15 | 2.86 | 0.66 | 1.72 | |
Interest coverage | 0 | 7.63 | 2.43 | 63.23 | -31.93 | |
Income quality | -5.18 | 0.93 | 7 | 3.89 | 1.45 | |
Dividend Yield | 0.08 | 0.08 | 0.1 | 0.07 | 0.13 | |
Payout ratio | -5.21 | 0.81 | 7.02 | 0.61 | -0.54 | |
Sales general and administrative to revenue | -0.79 | 0.05 | 0.23 | 0.03 | -0.02 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 6.73 | 18.24 | 6.61 | 18.87 | 20.33 | |
ROIC | 0 | 0.07 | 0.01 | 0.1 | -0.11 | |
Return on tangible assets | -0.01 | 0.06 | 0.01 | 0.09 | -0.11 | |
Graham Net | -6.61 | -6.53 | -6.69 | -6.19 | -6.99 | |
Working capital | 0 | 1.57M | 3.79M | -2.1M | 2.58M | |
Tangible asset value | 243.32M | 247.52M | 229.32M | 181.09M | 168.28M | |
Net current asset value | -134.69M | -123.96M | -124.92M | -107.4M | -120.87M | |
Invested capital | 0.37 | 0.36 | 0.14 | 0.16 | 0.27 | |
Average receivables | 8.59M | 10.15M | 8.43M | 4.97M | 5.15M | |
Average payables | 6.94M | 8.95M | 6.14M | 4.14M | 4.92M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | -4.04K | 158.17 | 349.01 | 51.23 | -74.08 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | -0.09 | 2.31 | 1.05 | 7.12 | -4.93 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.01 | 0.09 | 0.01 | 0.15 | -0.2 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-10-31 for Q4
Metric | History | 2020-10-31 | 2021-04-30 | 2021-10-31 | 2022-04-30 | 2022-10-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0 | 0 | 0 | 0 | 0 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | 0 | 0 | 0 | 0 | 0 | |
Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 0 | 0 | 0 | 0 | 0 | |
Enterprise value | 32.6M | 21.78M | 29.03M | 19.32M | 45.89M | |
P/E ratio | 0 | 0 | 0 | 0 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | 0 | 0 | 0 | 0 | 0 | |
PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
P/B Ratio | 0 | 0 | 0 | 0 | 0 | |
PTB ratio | 0 | 0 | 0 | 0 | 0 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0 | 0 | 0 | 0 | 0 | |
EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
Earnings yield | 0 | 0 | 0 | 0 | 0 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0.57 | 0.56 | 0.62 | 0.65 | 0.75 | |
Debt to assets | 0.36 | 0.36 | 0.38 | 0.39 | 0.43 | |
Net debt to EBITDA | 0 | 0 | 0 | 0 | 0 | |
Current ratio | 0 | 0 | 0 | 1.65 | 1.72 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0 | 0 | 0 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0 | 0 | 0 | 0 | 0 | |
ROIC | 0 | 0 | 0 | 0 | 0 | |
Return on tangible assets | 0 | 0 | 0 | 0 | 0 | |
Graham Net | 0 | 0 | 0 | 0 | 0 | |
Working capital | 0 | 0 | 0 | 2M | 2.58M | |
Tangible asset value | 229.32M | 185.91M | 181.09M | 153.76M | 168.28M | |
Net current asset value | -130.74M | -104.69M | -111.54M | -94.39M | -120.87M | |
Invested capital | 0.14 | 0.13 | 0.16 | 0.13 | 0.27 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 0 | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0 | 0 | 0 | 0 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
NHS Frequently Asked Questions
What is Neuberger Berman High Yield Strategies Fund Inc. stock symbol ?
Neuberger Berman High Yield Strategies Fund Inc. is a US stock , located in New york of Ny and trading under the symbol NHS
What is Neuberger Berman High Yield Strategies Fund Inc. stock quote today ?
Neuberger Berman High Yield Strategies Fund Inc. stock price is $7.605 today.
Is Neuberger Berman High Yield Strategies Fund Inc. stock public?
Yes, Neuberger Berman High Yield Strategies Fund Inc. is a publicly traded company.